Natural Mosquito-Pathogen Hybrid IgG4 Antibodies in Vector-Borne Diseases: A Hypothesis by Berlin Londono-Renteria et al.
September 2016 | Volume 7 | Article 3801
HypotHesis and tHeory
published: 29 September 2016
doi: 10.3389/fimmu.2016.00380
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Heinrich Korner, 
University of Tasmania, Australia
Reviewed by: 
Dirk Alexander Mielenz, 
University of Erlangen-Nuremberg, 
Germany  
Andreas Ludwig Lopata, 
James Cook University, Australia
*Correspondence:
Berlin Londono-Renteria  
blondono@uscmed.sc.edu
Specialty section: 
This article was submitted to 
Microbial Immunology, 
a section of the journal 
Frontiers in Immunology
Received: 31 March 2016
Accepted: 08 September 2016
Published: 29 September 2016
Citation: 
Londono-Renteria B, Cardenas JC, 
Troupin A and Colpitts TM (2016) 
Natural Mosquito-Pathogen Hybrid 
IgG4 Antibodies in Vector-Borne 
Diseases: A Hypothesis. 
Front. Immunol. 7:380. 
doi: 10.3389/fimmu.2016.00380
natural Mosquito-pathogen Hybrid 
igG4 antibodies in Vector-Borne 
diseases: a Hypothesis
Berlin Londono-Renteria1*, Jenny C. Cardenas2, Andrea Troupin1 and Tonya M. Colpitts1
1 Department of Pathology, Microbiology and Immunology, University of South Carolina School of Medicine, Columbia, SC, 
USA, 2 Clinical Laboratory, Hospital Los Patios, Los Patios, Colombia
Chronic exposure to antigens may favor the production of IgG4 antibodies over other 
antibody types. Recent studies have shown that up to a 30% of normal human IgG4 is 
bi-specific and is able to recognize two antigens of different nature. A requirement for 
this specificity is the presence of both eliciting antigens in the same time and at the same 
place where the immune response is induced. During transmission of most vector-borne 
diseases, the pathogen is delivered to the vertebrate host along with the arthropod saliva 
during blood feeding and previous studies have shown the existence of IgG4 antibodies 
against mosquito salivary allergens. However, there is very little ongoing research or 
information available regarding IgG4 bi-specificity with regard to infectious disease, par-
ticularly during immune responses to vector-borne diseases, such as malaria, filariasis, 
or dengue virus infection. Here, we provide background information and present our 
hypothesis that IgG4 may not only be a useful tool to measure exposure to infected 
mosquito bites, but that these bi-specific antibodies may also play an important role in 
modulation of the immune response against malaria and other vector-borne diseases in 
endemic settings.
Keywords: igG4, bi-specific, arthropod saliva, vector-borne diseases, malaria, dengue virus, mosquito
patHoGens and MosQUito saLiVa – a BrieF introdUCtion
Infectious diseases are one of the leading causes of mortality worldwide (1, 2). From this large 
group, the vector-borne diseases are among the leading causes of mortality and disability in 
developing countries (3, 4). The majority of arthropod-borne diseases lack a specific vaccine; 
thus, prevention relies predominantly on vector control interventions (5, 6). In the last decade, 
considerable effort has been put toward the dissection of arthropod factors that modulate the 
transmission of pathogens (7–9). Several studies have shown that during transmission, vector 
saliva plays an important role in the establishment of a successful infection and favors the pathogen 
survival by modulating the local immune responses (7, 10–14). Most salivary proteins (SPs) are 
highly immunogenic, able to elicit antibody production and memory responses (15, 16). During 
probing and feeding, mosquitoes deposit SP in the vertebrate host to facilitate the blood meal 
Abbreviations: ADE, antibody mediated enhancement; Ae, Aedes; BR1, B regulatory 1 cells; CL, cutaneous leishmaniasis; 
DENV, dengue virus; EBV, Epstein–Bar virus; FcR, fragment crystalizable region receptor; FS, Fogo Selvagem; gSG6-P1, sali-
vary gland protein-6 peptide 1; HIV, human immunodeficiency virus; Ig, immunoglobulin G (IgG) or E (IgE).; L, Leishmania; 
Lu, Lutzomyia; ML, mucosal leishmaniasis; Ph, phlebotomus; PKDL, post Kala-Azar dermal leishmaniasis; SP, salivary protein; 
VL, visceral leishmaniasis.
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intake (17–19). The immune response induced by arthropod 
saliva is mainly Th2, which favors the production of antibodies 
(20, 21). IgG4 antibodies are known to reflect repeated exposure 
to environmental antigens and allergens (22, 23). Additionally, 
recent research by our laboratory has found that exposure to 
mosquito saliva can be correlated with disease clinical presenta-
tion (15, 24, 25). Chronic exposure to mosquito bites induces 
higher IgG4 antibodies against SPs than other IgG subclasses 
(22, 26, 27), suggesting that this specific antibody subclass 
may be a marker of intense exposure to arthropod vectors (28, 
29). Here, we present a brief review on the antibody response 
against SPs and the hypothetical implication of IgG4 antibodies 
in  disease progression of several vector-borne diseases.
igG4: a speCiaL MoLeCULe
As a general characteristic, IgG4 is an effective immuno-regulator 
(23). This is due to the fact that, although IgG4 may act as a block-
ing antibody, it is not efficient in forming large immune com-
plexes (30). IgG4 antibodies are able to interact with the receptors 
FcγRI, FcγRIIA, FcγRIIB, FcγRIIC, and FcγRIIIA. Interestingly, 
the inhibitory receptor FcγRIIB has lower affinity for IgG1, IgG2, 
and IgG3 than the other Fc receptors (FcRs), but affinity is not 
lower for IgG4 (31). This interaction may be in part responsible 
for the anti-inflammatory properties of IgG4. In addition, IgG4 
antibodies block IgE-mediated inflammatory responses by com-
peting for antigen recognition sites, thus inhibiting Fcε-receptor 
cross-linking and further signaling (32, 33). IgG4 is the only 
IgG subclass with equal affinity for activating FcRs and for the 
inhibitory receptor FcγRIIB (34). If IgG4 co-interact with both 
inhibiting and activating receptors, the result would be inhibition 
of effector cell responses (34, 35).
Naïve B cells express a monomeric membrane-bound B 
cell receptor normally as IgM or IgD antibodies (36, 37). After 
activation of such B cells and aided by specific cytokines, rear-
rangement of the antibody heavy chain locus through class switch 
recombination results in the expression of a new isotype (i.e., 
IgG). In the case of IgG4, production relies on the Th2 cytokines 
IL-4 and IL-13 (38). The Th2-associated cytokine, IL-10, is a key 
factor in the activation of IgG4 producing B cells (39). Secretion 
of IL-10 will skew immune response to the production of IgG4 
antibodies over other IgG subclasses. IL-10-producing B cells 
regulate pro-inflammatory immune responses and a lack of them 
can lead to exacerbated chronic inflammation (40, 41). Previous 
studies showed that IgG4 may be selectively produced in human 
B regulatory 1 (BR1) cells and that allergen-specific B cells present 
increased expression of both IL-10 and IgG4 (42). Distinctive 
from other IgG subtypes, IgG4 is the only antibody class that is 
able to recognize two antigens of different nature; therefore, it is 
often termed a bi-specific antibody (23). A requirement for this bi-
specificity is that both eliciting antigens must be present at the same 
time and at the same place when the immune system is stimulated 
(43). This is the case of naturally acquired infections transmitted 
by arthropods where pathogens, such as parasites or viruses are 
delivered into human skin imbibed in saliva with SP (44).
IgG4 molecules are synthesized the same way as all the 
other IgG subclasses (23). However, extensive research has 
demonstrated important sequence differences among all IgG 
subclasses that confect various levels of stability between chains 
in the hinge region (45, 46). These studies shown that one single 
substitution of a proline for an serine in the light chain allows 
IgG4 molecules to undergo a process called the “half-molecule 
exchange” where one antibody molecule directed against a 
specific antigen has the capacity of “exchanging” a half-molecule 
(a heavy chain and an attached light chain) with another IgG4 
molecule synthetized against another non-related antigen 
(45–48) (Figure  1). Normally, a single B cell will produce IgG 
molecules with identical copies of a heavy chain determining 
the immunoglobulin isotype (e.g., G) and two identical copies of 
light chains (κ or λ) (49, 50). During the half-molecule exchange 
process, hybrid IgG4 molecules could contain two heterogeneous 
light chains (i.e., κ/λ instead of κ/κ or λ/λ). A recent publication 
described that hybrid bi-specific IgG4 κ/λ antibodies represent 
approximately up to 30% of the total IgG4 antibodies in human 
sera (51). Unfortunately, the exact mechanism involved with the 
in vivo generation of specific IgG4 molecules is largely unknown.
Another special characteristic of IgG4 antibodies is their 
ability to interact with other IgG subclasses, particularly IgG1, in 
such a way as to alter/block their functionality and FcR binding 
(48). Specifically, previous studies have found that the Fc portion 
of IgG4 is able to interact with other IgG antibodies in an Fc–Fc 
fashion due to conformational changes that allows interaction 
between CH3 motifs from both molecules (45, 48). This interac-
tion is specially favored when the target, IgG1 or another IgG4 
molecule, is coupled to a solid phase (Figure 2). Fc–Fc interactions 
between two IgG4 may potentially be an intermediated step in the 
formation of bi-specific IgG4 molecules, allowing the contact and 
further recombination of two IgG4 molecules. A more detailed 
description of the Fc–IgG4 interactions with other Fc–IgG and 
their potential implication in vivo is explained in detail by Rispens 
et al. (48) and Davies et al. (45).
In the case of vector-borne human diseases, anti-SP IgG4 
may undergo this half-molecule exchange with IgG4 molecules 
against a pathogen. Since IgG4 antibodies are often present in 
individuals who are chronically exposed to mosquito saliva 
allergens, we hypothesize that some of these antibodies may form 
hybrid bi-specific molecules with pathogen-specific IgG4 during 
natural transmission of vector-borne diseases. This hypothesis is 
also based on the fact that mosquito saliva alone is able to increase 
the level of IL-10 in exposed tissues creating a favorable environ-
ment for the production of IgG4 antibodies against the antigens 
present. If those antibodies are against two different antigens, the 
half-arm exchange may be induced.
The majority of research on the characteristics of bi-specific 
antibodies has been focused on artificial antibodies for cancer 
treatment or the role of natural bi-specific antibodies in autoim-
mune diseases, such as rheumatoid arthritis (RA) (52–54). The 
mechanisms involving IgG4 in autoimmune diseases is still not 
understood, but findings suggest that the presence of natural 
bi-specific antibodies in serum from RA patients may serve as 
indicators for disease remission (53). Additionally, artificial 
bi-specific antibodies are among the most promising treat-
ment choices for cancer and inflammatory-mediated diseases 
over monoclonal antibodies because they can simultaneously 
FiGUre 1 | schematic representation of Fab-arm exchange between igG molecules: changes in heavy chain sequences makes the inter-chain 
interactions weaker and favoring intra-chain interactions in a way that allows arm disassembly and further rearrangement between molecules 
recognizing antigens of different nature. This reaction can be simulated in vitro under reducing conditions with glutathione.
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target two different antigens and improve therapeutic out-
comes (55, 56). Two options of artificial bi-specific antibodies 
are already available in the market and several others are in 
clinical trials (55). However, there is a stark lack of research 
with regard to infectious diseases transmitted by arthropods 
and the participation, if any, of bi-specific IgG4 in the immune 
response against them. We believe that possible missing clues 
in vaccine or/and treatment development for malaria and other 
vector-borne diseases may be hidden within the properties of 
this double-handed molecule known as IgG4.
Bi-specific IgG4 molecules are stimulated in an environment 
of diverse antigens. For example, previous studies have shown 
that a single IgG4 molecule is able to bind grass/pollen antigens 
and house dust mite antigens at the same time (43). In the case of 
allergens, such as mosquito saliva, which is composed of a diverse 
cocktail of molecules, the IgG4 bi-specificity could be elicited 
against the various salivary components producing “SP–SP” bi-
specific IgG4 (Figure 3A). However, in the presence of pathogen/
saliva mixture (delivered via an infective insect bite), a proportion 
of “pathogen-SP” IgG4 would likely be produced (Figure  3B). 
Indeed, chronic exposure to mosquito salivary antigens has been 
proposed to play a role in immunity against chronic versions of 
several vector-borne diseases, such as filariasis, leishmaniasis, 
and malaria (57–59), by stimulating the production of pathogen-
SP IgG4 bi-specific antibodies.
The human immune response against vector-borne pathogens 
often involves the production of IgG1 antibodies with high pro-
inflammatory activities that are able to clear most pathogens. 
If conformational changes are induced at the Fc portion of an 
antigen-bound IgG1 molecule, a significant IgG4-mediated 
response against SPs and/or pathogen antigens may block an 
IgG1-mediated response, which would have a profound effect on 
the fate of infectious disease progression and immune response 
Thus, IgG4 and bi-specific IgG4 antibodies may represent attrac-
tive examples of how the immune response to environmental 
antigens could potentially modulate the fate of infectious diseases 
in humans (35).
igG4 and parasitiC inFeCtions
Filariasis
Human filariasis (lymphatic filariasis, Onchocerciasis, and 
Loiasis) is group of parasitic infections often transmitted by 
arthropods to humans and animals (60–62). With the exception 
FiGUre 3 | a hypothetical representation of the hybrid igG4 
formation in vector-borne diseases. (a) In the absence of infection in the 
mosquito, probing will inject saliva proteins into the vertebrate host during 
blood feeding. Thus, antibodies will be made against mosquito proteins only 
(BLUE). (B) In the presence of infection in the mosquito, the pathogen will be 
delivered in the skin along with the salivary proteins. Antibodies will be made 
that recognize mosquito proteins (BLUE) as well as pathogen proteins 
(RED). The chronic exposure to different antigens will stimulate the 
production of IgG4 molecules that will undergo fab-arm exchange when two 
different antigens are present, resulting in bi-specific antibody molecules 
(BLUE AND RED).
FiGUre 2 | proposed anti-inflammatory mechanism for igG4 antibodies. (a) Fc–Fc interaction between IgG4 and IgG1 may block access to activating Fcγ 
receptors on effector cells. (B) Antigen-binding competition against IgE avoids/decreases cross-link with activating Fcε receptors.
4
Londono-Renteria et al. Bi-Specific IgG4 Responses in Vector-Transmitted Diseases
Frontiers in Immunology | www.frontiersin.org September 2016 | Volume 7 | Article 380
of Dracunculus medinensis, all filarial worms use insects as 
intermediate hosts (63). These diseases are important causes of 
disability and physical deformity in developing countries (62). 
It is calculated that at least one-fifth of the global population is 
at risk and there is not any commercially available vaccine (64). 
However, in spite of challenges in program coverage and 
compliance, significant progress has been made in reducing 
the incidence of filarial infections by mass drug administration 
programs (65).
As in the rest of human helminthiasis, IgG4 antibody response 
is the hallmark of filarial infections. Previous studies have shown 
that up to 95% of IgG antibodies against filarial worms belong to 
the IgG4 subclass (66, 67). Filarial parasites preferentially induce 
the production of IgG4 antibodies to evade immune response 
in the infected host; thus, filarial infections are often chronic 
(68). Adjobimey and Hoerauf (67) suggested that the immune 
regulatory properties of IgG4 in filarial infection could be associ-
ated with the half-molecule exchange property of this antibody 
(67). Mosquitoes from the genus Aedes, Anopheles, Culex, and 
Mansonia can all transmit filarial parasites. Whether bi-specific 
antibodies are elicited against salivary/pathogen antigens in 
filariasis or other helminthic diseases remains to be investigated, 
though it seems a likely scenario.
Previous studies demonstrate that the levels of IgG antibody 
subclasses during infection depend on filarial transmission 
intensity. In higher transmission areas, antigen-specific IgG4 
levels against different parasite stages (microfilaria versus adults 
stages) are associated with parasite carriage and asymptomatic 
infection (68, 69), In fact, people with asymptomatic filarial infec-
tion present significantly higher IgG4 antibody levels than people 
with severe disease. By contrast, lower IgG4 antibody levels, along 
with high titers of IgE, are present in severe cases (70–72). It is 
proposed that IgG4 antibody levels in filarial infected patients 
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is associated with the blocking effect of the IgE mediated, often 
exacerbated, pro-inflammatory responses (61).
Malaria
Malaria is currently the most prevalent parasitic disease transmit-
ted by mosquitoes in the world; it is caused by parasites of the 
genus Plasmodium (73). Several Plasmodium species can cause 
disease in human but it is Plasmodium falciparum that is the 
single species responsible for majority of human deaths (74, 75). 
In spite of major significant advances in the knowledge of malaria 
transmission and several vaccine trials in recent years, there is 
still not a single vaccine against Plasmodium spp. infection com-
mercially available (76). A vaccine against malaria is desperately 
needed to prevent the nearly 500,000 deaths from this disease 
each year, most of them children under the age of 5 years (77–79). 
Interestingly, in endemic areas, natural “protective immunity” is 
developed over decades of exposure to infected mosquito bites 
(80). People who develop this type of immunity are partially pro-
tected against severe disease and more dangerous symptoms. This 
would mean that the longer someone lives in an endemic area, the 
more protected the individual would be against severe malaria. 
In fact, the association between asymptomatic malaria carriers 
and age has been well documented (81–85). Unfortunately, this 
immunity is short-lived and may wane once the person leaves 
the endemic, mosquito-rich area or when exposure becomes less 
constant (i.e., travel, emigration) (80, 86). When this happens, 
the body returns to a “naïve” state and the person may develop 
symptoms, and even severe disease, upon a new infection with 
Plasmodium (87).
In humans, immune response against malaria seems to be 
mediated by “cooperation” between cellular and antibody-
mediated responses. The main antibodies associated with protec-
tive immunity against malaria are the IgG subclasses, IgG1 (88, 
89). Since IgG4 may interfere with the activity of other antibody 
subclasses, we hypothesize that IgG1-mediated responses against 
Plasmodium could be influenced by an increase in IgG4 antibod-
ies induced by the presence of saliva. These IgG4 antibodies may 
bind Plasmodium-bound IgG1 antibodies blocking Fc-receptor-
mediated responses, opsonization and/or complement activation, 
consequently, enhancing parasite survival. It is also possible that, 
in the presence of saliva, bi-specific Plasmodium–Anopheles IgG4 
antibodies are induced and play a role in developing protective/
detrimental immune responses during malaria infection.
One of the main SPs in the principal malaria vector in Africa, 
Anopheles gambiae, is the salivary gland protein 6 (gSG6), a small 
proteins exclusively expressed in adult female salivary glands 
that plays a role blood feeding (90). Antibodies against a peptide 
derivative from this protein, the gSG6-P1, have been validated as 
a marker for Anopheles bite exposure (91, 92). The gSG6 protein is 
recognized by IgG4 antibodies in serum from people chronically 
exposed to Anopheles bites (27, 93). Although the presence of 
bi-specific IgG4 antibodies or a direct correlation between gSG6-
IgG4 and Plasmodium IgG1 has not yet been evaluated, a recent 
study suggested a negative effect of mosquito bite exposure on 
the IgG1-mediated immune response against malaria. This study 
showed that children with higher levels of exposure to Anopheles 
bites presented lower IgG1 responses against Plasmodium antigens 
and parasitemia was significantly correlated with IgG1 antibody 
levels (94), suggesting an impact of immunity against SPs in the 
immune response against infection in pediatric populations. The 
impact of anti-salivary immunity in adults was not described in 
this study. It is possible that high exposure to mosquito bites in 
children can induce anti-SP IgG4 antibodies capable of binding 
Plasmodium-specific IgG1 and block its activity; therefore, result-
ing in more symptomatic disease. However, extensive further 
research is needed to evaluate whether there is a correlation 
between the anti-SP IgG/IgG4 ratio and symptomatic disease in 
children as well as whether bi-specific antibodies play a role in 
age-dependent protection/pathogenesis in malaria.
Leishmania
Leishmaniasis is a group of parasitic diseases [cutaneous, 
mucocutaneous and visceral leishmaniasis (VL)] caused by 
parasites of the genus Leishmania spp. Leishmaniasis is trans-
mitted by Phlebotomus spp. (Old World) and Lutzomyia spp. 
(New World) sandflies (95, 96). Cutaneous leishmaniasis (CL) 
is often presented as chronic lesions developed from months 
to years. Previous studies have shown an association between 
disseminated CL forms of leishmaniasis and IgG4 antibody 
levels (97). In fact, proper healing is often associated with a 
Th1-mediated response while disseminated disease is associated 
with Th2 responses. CL and mucocutaneous leishmania (ML) 
infections are characterized by successively higher specific 
antibody titers that reflect the length of infection and parasite 
loads (98). High antibody titers can also be detected in VL due 
to a polyclonal activation of B cells (99). VL is a serious parasitic 
disease caused by the protozoan Leishmania donovani (Asia) 
and L. infantum/L. chagasi with more than 200 million people at 
risk globally (95, 100). The Post-kala-azar dermal leishmaniasis 
(PKDL) is a complication presenting in patients infected with 
L. donovani that have recovered from VL (101). It has been 
found that IgG4 is significantly elevated in PKDL compared 
to VL, especially in pediatric populations (102). Higher IgG4 
antibody levels have also been observed in people with active 
VL in comparison to treated patients or those with subclinical 
disease (103). Additionally, a decrease in the IgG4 antibody titer 
has been observed in children with VL after treatment, suggest-
ing that IgG4 may be a suitable immunological marker for the 
assessment of drug treatment (104).
It has been well documented that saliva from sandflies 
enhances Leishmania infection during the first stages of the infec-
tion. This is thought to be due to the immunosuppressive effect of 
several saliva components on macrophages and T cells (105–108). 
Interestingly, immunity against sand fly salivary molecules may 
confer protection against disease (108, 109). In mouse models, 
the protection observed in pre-exposed animals to sandfly saliva 
involved a strong induction of Th1 response and delayed-type 
hypersensitivity (DTH) response reaction against saliva that 
creates a detrimental environment for the parasite (110). These 
studies showed that the immune response against the phleboto-
mine sandfly’s SPs has modulatory effects on disease pathogenesis 
and some of these proteins are considered candidates for vaccine 
or drug synthesis (111, 112). It is hypothesized that the study of 
mosquito salivary factors with similar activity could lead to novel 
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candidates for other arthropod transmitted diseases (11, 113). 
In addition, previous studies have shown that people exposed 
to sandfly bites present specific antibodies against the saliva of 
the main vectors in the area where they reside and little or no 
cross-reactivity to other sandfly species. People with active leish-
maniasis present significantly higher IgG antibody levels against 
SPs of the main vector when compared with healthy individuals 
living in the same area (114).
One study demonstrated that IgG4 antibodies are the main 
antibody subclass against SPs of the Ph. papatasi sandfly (115). It 
has been shown that previous exposure to the American sandfly 
Lu. intermedia can induce a significant increase in IL-10 expres-
sion resulting in exacerbation of infection after challenge with 
Leishmania braziliensis (116, 117), although positive correlation 
between antibody response to saliva and cellular response to 
Leishmania has not been reported. Importantly, individuals 
seropositive to saliva are twice more likely to develop CL (118). 
Infection by L. braziliensis is responsible for the majority of ML 
characterized by highly destructive mucosal lesion. ML often fol-
lows skin lesions even decades before the mucosal involvement 
(119). In that time, it is very likely that people continue being 
exposed to vector bites, which may induce the production of bi-
specific IgG4 antibodies against mosquito proteins and pathogen 
proteins.
arBoVirUses: a FoCUs on denGUe 
and antiBody-Mediated responses
Dengue is a disease caused by dengue virus (DENV), which is 
transmitted by Aedes mosquitoes in tropical and subtropical 
regions (4). While the majority of DENV infections result in 
little or no disease, a small proportion of cases progresses to 
severe forms: dengue with warning signs and severe dengue 
also known as dengue hemorrhagic fever (DHF) and dengue 
shock syndrome (DSS) (120). It is thought that cross-reactive 
but sub-neutralizing IgG antibodies developed during the first 
DENV infection may enhance a second infection with a dif-
ferent serotype in a phenomenon termed antibody-dependent 
enhancement (ADE) (121–123). During ADE, it is thought 
that these sub-neutralizing antibodies may increase viral load 
by enabling entry into immune cells via the Fc gamma receptor 
(FcγR) (124). ADE is a significant risk factor for severe dengue 
fever (125, 126). Since IgG4 molecules are able to interact with 
different FcγR (31), it is imperative to study whether bi-specific 
IgG4 antibodies play a role in ADE.
Currently, considerable research in DENV pathogenesis 
is focused on pathogen-induced disease severity (127–130). 
Although this is of relevance, there is also a need for studies 
on the role of arthropod vector factors involved in pathogen 
infectivity and disease development. Interestingly, previous 
studies have shown that pathogen infection of mosquito salivary 
gland induces changes in the composition of saliva (131, 132). 
Recent studies have also shown a significant correlation between 
the antibody levels against these upregulated mosquito SPs and 
exposure to disease; thus, these proteins have been proposed 
as potential markers of exposure to infective bites (131). We 
speculate that a higher proportion of bi-specific IgG4 antibodies 
could be elicited against these upregulated proteins along with 
the pathogen, since these proteins are in higher concentration in 
the presence of the pathogen.
saLiVary protein igG4-Mediated 
patHoLoGy
Previously, studies have demonstrated that bi-specific IgG4 
antibodies are naturally produced in autoimmune diseases 
and other IgG4-related diseases (53, 54, 133). One autoim-
mune disease related to IgG4-mediated responses is the Fogo 
Selvagem (FS). In patients with FS, pathogenic autoantibodies 
of the IgG4 class react against desmoglein1 (Dsg1), a trans-
membrane glycoprotein component of vertebrate epithelial 
cells (134). It has been demonstrated that FS incidence overlaps 
significantly with exposure to Lu. longipalpis sandflies in Brazil 
(135). Interestingly, the antibody response against one specific 
sandfly protein, LJM11, is associated with an IgG4-mediated 
disease characterized by an IgG4 cross-reactivity between two 
antigens of different nature. It was also shown that antibodies 
recognizing Dsg1 during FS disease also recognize the SP LJM11, 
and that antibodies recognizing LJM11 can cross-react with 
anti-Dsg1 monoclonal autoantibodies derived from FS patients. 
The authors suggest that insect bites may induce a cross-reactive 
IgG4 antibody response, which then leads to FS disease. Their 
findings demonstrate a relationship between a non-infectious 
antigen (environmental) and the development of an autoimmune 
disease (136). Although the presence of bi-specific IgG4 was not 
evaluated, these findings suggest the potential involvement of 
vector saliva IgG4-mediated-pathology.
non-VeCtor Borne CHroniC ViraL 
diseases and igG4
In general, viral infections induce the production of neutral-
izing IgG1 and IgG3 antibodies over IgG4 (137, 138). However, 
it is possible that viruses responsible for chronic infections may 
also induce significant levels of IgG4 antibodies. This could be 
the case with infections by hepatitis B or C viruses, cytomegalo-
virus, Epstein–Bar virus (EBV), and human immunodeficiency 
virus (HIV), among others. Unfortunately, the role of IgG4 in 
the previously mentioned diseases has been rather neglected 
and conflicting results are found in the literature. For instance, 
in the case of HIV, one study found insignificant differences in 
IgG4 levels between HIV-1 positive patients and healthy con-
trols (139), while other studies have shown that IgG4 antibody 
levels are significantly lower in HIV-1 patients (140–142). In 
addition, progression to AIDS may have a negative impact on 
IgG4 antibody concentration (143) since rapidly progressing 
patients present higher antibody levels when compared to slowly 
progressing individuals (141). Another study described a Th2 
response characterized by high IgG4 antibody levels in children 
with advanced HIV-1 infections, which is thought to contribute 
to disease progression (144). By contrast, infection with EBV 
has been previously associated with IgG4-related lymphad-
enopathy with an increase in the number of EBV-infected cells, 
suggesting a direct association between EBV and IgG4-related 
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disease (145–147) The specific mechanism involving these rela-
tionships are still under investigation. Consequently, extensive 
further investigation is needed to characterize the role of IgG4 
antibodies in viral chronic diseases as well as to determine the 
existence of hybrid IgG4 molecules recognizing different viral 
antigens or tissue-viral antigens.
tHe HypotHesis and 
preLiMinary data
In a given area, people may be exposed to hundreds of mos-
quito bites from different mosquito species (148). Previous 
studies have shown that levels of anti-SP IgG4 antibodies may 
increase with age and they are dependent of the transmission 
intensity (28, 29, 149) (Figure 4A). Chances for bi-specific IgG4 
antibodies to be randomly generated, increases with time and 
exposure intensity (Figures  4B–D). Furthermore, arthropod 
saliva contains dozens of proteins, each one eliciting different 
responses in a given host (150). Thus, we decided to test the 
hypothesis that virally infected mosquito saliva is able to induce 
the production of bi-specific IgG4 antibodies using serum from 
people exposed to DENV and Aedes mosquito bites. For this 
pilot test, we selected 30 serum samples from DENV positive 
(n = 24) and control (n = 6) human subjects living in an area 
where Ae. aegypti is the main vector of DENV, and Ae. albopictus 
was recently introduced. Samples were tested for the presence 
of IgG4 antibodies in an ELISA-based assay (Figure 5A). Our 
results demonstrate that the main antibody subclass against Ae. 
aegypti SP is the IgG4, consistent with previous studies (22, 71). 
We next examined whether these IgG4 antibodies are bi-specific 
by testing their ability to bind both DENV antigens and Aedes SP. 
We found that our serum samples did contain bi-specific IgG4 
antibodies (Figures 5B,C). We also found that more antibodies 
bound both DENV and Ae. aegypti SP than Ae. albopictus SP 
(Figures 5B,C). However, this was expected, as the individuals 
in the study had been exposed longer to Ae. aegypti. We are 
FiGUre 4 | Hypothetical chronic progression of total and bi-specific igG4 antibodies according to disease transmission settings. (a) Total IgG4 
antibodies develop under chronic exposure to antigens. (B–d) Graphic representation of the bi-specific IgG4 antibody levels in the presence of exposure to high 
mosquito population/no pathogen transmission (B), high mosquito population/high pathogen transmission (C), and low mosquito population/low pathogen 
transmission (d). Antibody levels will depend on the time and magnitude of exposure to antigens.
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FiGUre 5 | Bi-specific igG4 molecules in denV infection. Serum samples were obtained from febrile patients seeking dengue fever diagnosis. The presence of 
antibodies binding mosquito salivary proteins (SPs) and DENV antigen was evaluated in an ELISA-based test: plates were coated with Ae. aegypti SP and incubated 
with human serum. After washing, DENV particles were added to the plates followed by incubation with an anti-Flavivirus HRP labeled antibody. Optical densities 
(OD) were read at 450 nm. (a) IgG antibody subclass distribution in febrile individuals with (+) and without (−) active viremia. (B) Graphical representation of ELISA 
methods. (C) Bi-specific antibody levels against SP of the main Aedes species in the area. The inclusion of human subjects to evaluate the immune response 
against mosquito saliva was reviewed and approved by the IRB committees at the University of Pamplona (Colombia).
currently isolating the hybrid IgG4 molecules from these sam-
ples to test their effect on DENV infection.
Our experiments suggest the existence of IgG4 molecules 
binding DENV and SP, and they are an approximation of the 
effect of immunity against mosquito saliva in viral infections. 
More specific and accurate testing must be done to evaluate single 
bi-specific IgG4 antibodies and demonstrate the role of hybrid 
IgG4 molecules in vector-transmitted diseases.
ConCLUdinG reMarKs
It is of pivotal importance to determine whether there is produc-
tion of saliva-pathogen IgG4 bi-specific antibodies during human 
infection with vector-borne pathogens, as well as the SPs that are 
involved in such a response. We speculate that in order to reach 
protective immunity against diseases, such as malaria through 
vaccination, treatment options should induce and resemble the 
natural immunity-building experience undergone by individuals 
living in areas with intense malaria transmission.
The study of the role of mosquito saliva immunity and anti-
bodies against both pathogen and vector, as a tool to evaluate 
and monitor the exposure to infected mosquito bites, would 
improve control interventions and guide new strategies for 
protection and elimination. We have presented here evidence 
that IgG4-mediated responses are present in vector-borne dis-
eases and that both arthropod saliva and the immune response 
against it may favor the formation of pathogen/mosquito bi-
specific IgG4 antibodies. We hypothesize that bi-specific IgG4 
is formed during chronic exposure to both mosquito bites and 
pathogen infection. Extensive additional research is necessary 
to characterize the nature of bi-specific antibodies and what 
role they may play in pathogenesis of or protection against 
vector-borne diseases.
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